|
Online Database of Chemicals from Around the World | 产品搜索 | 产品提交 | 产品推广 |
网站主页 >> 化工产品目录 >> Oprozomib>> 市场分析报告 |
Oprozomib市场分析报告 |
|
Global Market Report of Oprozomib (CAS 935888-69-0) December 2024 Hematological Malignancies: Multiple Myeloma (MM) – Early and Robust Diagnosis along with New Treatment Options can have Considerable Impact on Management of the Disease While targeting unmet needs in the treatment of hematological malignancies/ cancer through innovative drug development strategies have witnessed favorable outcomes, the specific choice of the therapies is dependent on the identification of important ... Global 20s Proteasome Market Growth 2024-2030 ... data, market segmentation by Type (e.g., Marizomib, Oprozomib), and regional breakdowns. Market Drivers ... and value. Segmentation by type Marizomib Oprozomib Carfilzomib VPEA-002 Others Segmentation ... Global 20s Proteasome Market Report 2021 ... USD—— Product Type Segmentation Marizomib Oprozomib Carfilzomib VPEA-002 Industry Segmentation ... Global 20s Proteasome Market Status, Trends and COVID-19 Impact Report 2022 ... USD—— Product Type Segmentation Marizomib Oprozomib Carfilzomib VPEA-002 Application Segmentation ... Global 20s Proteasome Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028 ... . Market segment by Type, covers Marizomib Oprozomib Carfilzomib VPEA-002 Others Market ... 20s Proteasome Market, Global Outlook and Forecast 2022-2028 ... Segment Percentages, by Type, 2021 (%) Marizomib Oprozomib Carfilzomib VPEA-002 Others Global ... Treating Refractory Hematological Malignancies - Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A Summary: The report (ToC) provides an overview of the therapies for Multiple Myeloma (Newly diagnosed - NDMM and relapsed/ refractory - RRMM), unmet need, and limitations of the current standard of care (SoC) for relapsed and refractory MM pts. The report ... Therapeutic Class Overview: Treating Refractory Hematological Malignancies Targeting unmet needs in the treatment of cancer/ hematological malignancies through innovative drug development strategies have witnessed favorable outcomes. Over the past decade, Proteasome inhibitor, Velcade (bortezomib) and the immunomodulatory drugs ... 20s Proteasome - Pipeline Review, H2 2020 20s Proteasome - Pipeline Review, H2 2020 SUMMARY According to the recently published report '20s Proteasome - Pipeline Review, H2 2020'; 20s Proteasome pipeline Target constitutes close to 9 molecules. Out of which approximately 6 molecules are developed ... 2023-2028 Global and Regional 20s Proteasome Industry Status and Prospects Professional Market Research Report Standard Version ... Inc Celgene Corp By Types: Marizomib Oprozomib Carfilzomib VPEA-002 Others By Applications ... Global 20s Proteasome Market Research Report 2024(Status and Outlook) ... Corp Market Segmentation (by Type) Marizomib Oprozomib Carfilzomib VPEA-002 Others Market ... |